| Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, MJ Hall, ... New England Journal of Medicine 381 (4), 317-327, 2019 | 2257 | 2019 |
| Pancreatic cancer: a review W Park, A Chawla, EM O’Reilly Jama 326 (9), 851-862, 2021 | 1338 | 2021 |
| Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology MA Tempero, MP Malafa, M Al-Hawary, H Asbun, A Bain, SW Behrman, ... Journal of the National Comprehensive Cancer Network 15 (8), 1028-1061, 2017 | 1037 | 2017 |
| Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303) HL Kindler, D Niedzwiecki, D Hollis, S Sutherland, D Schrag, H Hurwitz, ... Journal of Clinical Oncology 28 (22), 3617-3622, 2010 | 1019 | 2010 |
| Extracellular vesicle and particle biomarkers define multiple human cancers A Hoshino, HS Kim, L Bojmar, KE Gyan, M Cioffi, J Hernandez, ... Cell 182 (4), 1044-1061. e18, 2020 | 1001 | 2020 |
| Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection I Endo, M Gonen, AC Yopp, KM Dalal, Q Zhou, D Klimstra, M D'Angelica, ... Annals of surgery 248 (1), 84-96, 2008 | 968 | 2008 |
| Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ... Jama 317 (23), 2392-2401, 2017 | 898 | 2017 |
| Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group–directed intergroup trial … PA Philip, J Benedetti, CL Corless, R Wong, EM O'Reilly, PJ Flynn, ... Journal of clinical oncology 28 (22), 3605-3610, 2010 | 755 | 2010 |
| Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer AA Khorana, GA Soff, AK Kakkar, S Vadhan-Raj, H Riess, T Wun, ... New England Journal of Medicine 380 (8), 720-728, 2019 | 732 | 2019 |
| Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer LA Rojas, Z Sethna, KC Soares, C Olcese, N Pang, E Patterson, J Lihm, ... Nature 618 (7963), 144-150, 2023 | 702 | 2023 |
| Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial EM O’Reilly, DY Oh, N Dhani, DJ Renouf, MA Lee, W Sun, G Fisher, ... JAMA oncology 5 (10), 1431-1438, 2019 | 609 | 2019 |
| Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ... Journal of clinical oncology 37 (4), 286-295, 2019 | 592 | 2019 |
| Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma MA Shah, RK Ramanathan, DH Ilson, A Levnor, D D'Adamo, E O'Reilly, ... Journal of Clinical Oncology 24 (33), 5201-5206, 2006 | 585 | 2006 |
| Gallbladder cancer (GBC): 10‐year experience at memorial Sloan‐Kettering cancer centre (MSKCC) A Duffy, M Capanu, GK Abou‐Alfa, D Huitzil, W Jarnagin, Y Fong, ... Journal of surgical oncology 98 (7), 485-489, 2008 | 567 | 2008 |
| Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face F Fata, E O'Reilly, D Ilson, D Pfister, D Leffel, DP Kelsen, GK Schwartz, ... Cancer 86 (10), 2034-2037, 1999 | 538 | 1999 |
| Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma JM Herman, DT Chang, KA Goodman, AS Dholakia, SP Raman, ... Cancer 121 (7), 1128-1137, 2015 | 536 | 2015 |
| Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing D Mandelker, L Zhang, Y Kemel, ZK Stadler, V Joseph, A Zehir, ... Jama 318 (9), 825-835, 2017 | 509 | 2017 |
| Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, M Capanu, ... Clinical Cancer Research 24 (17), 4154-4161, 2018 | 508 | 2018 |
| Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB … AP Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O'Neil, ... Journal of Clinical Oncology 34 (15_suppl), 3504-3504, 2016 | 507 | 2016 |
| Intrahepatic cholangiocarcinoma: expert consensus statement SM Weber, D Ribero, EM O'Reilly, N Kokudo, M Miyazaki, TM Pawlik Hpb 17 (8), 669-680, 2015 | 494 | 2015 |
